Literature DB >> 4056852

Pharmacokinetics of 11C-BCNU in experimental brain tumor.

K Sako, M Diksic, S Farrokhzad, Y L Yamamoto, W Feindel.   

Abstract

Wistar rats implanted intracerebrally with AA ascites tumor were injected seven or eight days later with 11C-labelled BCNU. Radioactive compounds in samples of plasma, tumor, and contralateral brain were identified after injection at intervals by doing chloroform extraction and thin layer radiochromatography. At 60 min after injection radioactivity levels were 56% higher in the tumor than in contralateral brain. This increase was due mainly to 2-chlorethyl isocyanate, which binds to amino groups and/or nucleic acid. The results demonstrated both a higher concentration and a faster decomposition of BCNU in the tumor.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4056852     DOI： 10.1007/BF00165183

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  24 in total

1.  Experimental evaluation of potential anticancer agents VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia.

Authors:  F M SCHABEL; T P JOHNSTON; G S McCALEB; J A MONTGOMERY; W R LASTER; H E SKIPPER
Journal:  Cancer Res       Date:  1963-06       Impact factor: 12.701

2.  Interrelationships of some chemical, physicochemical, and biological activities of several 1-(2-haloethyl)-1-nitrosoureas.

Authors:  G P Wheeler; B J Bowdon; J A Grimsley; H H Lloyd
Journal:  Cancer Res       Date:  1974-01       Impact factor: 12.701

3.  The uptake, distribution, and antitumor activity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in the murine glioma.

Authors:  V A Levin; W R Shapiro; T P Clancy; V T Oliverio
Journal:  Cancer Res       Date:  1970-10       Impact factor: 12.701

4.  Microsomal metabolism of nitrosoureas.

Authors:  D L Hill; M C Kirk; R F Struck
Journal:  Cancer Res       Date:  1975-02       Impact factor: 12.701

5.  BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea; NSC-409962) in the treatment of malignant brain tumor--a preliminary report.

Authors:  M D Walker; B S Hurwitz
Journal:  Cancer Chemother Rep       Date:  1970-08

6.  The physiological disposition of the carcinostatic 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in man and animals.

Authors:  V T DeVita; C Denham; J D Davidson; V T Oliverio
Journal:  Clin Pharmacol Ther       Date:  1967 Jul-Aug       Impact factor: 6.875

7.  [Effect of dexamethasone on tumorous brain edema--changes in regional cerebral blood flow and glucose utilization].

Authors:  N Arita; L Y Yamamoto; W Feindel
Journal:  No To Shinkei       Date:  1983-11

8.  Relationship of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) pharmacokinetics of uptake, distribution, and tissue/plasma partitioning in rat organs and intracerebral tumors.

Authors:  V A Levin; P A Kabra; M A Freeman-Dove
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

9.  The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the plasma pharmacokinetics and biotransformation of BCNU.

Authors:  V A Levin; J Stearns; A Byrd; A Finn; R J Weinkam
Journal:  J Pharmacol Exp Ther       Date:  1979-01       Impact factor: 4.030

10.  Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma.

Authors:  S B Green; D P Byar; M D Walker; D A Pistenmaa; E Alexander; U Batzdorf; W H Brooks; W E Hunt; J Mealey; G L Odom; P Paoletti; J Ransohoff; J T Robertson; R G Selker; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  Cancer Treat Rep       Date:  1983-02
View more
  1 in total

1.  Pharmacokinetics of 11C-labelled BCNU and SarCNU in gliomas studied by PET.

Authors:  S Mitsuki; M Diksic; T Conway; Y L Yamamoto; J G Villemure; W Feindel
Journal:  J Neurooncol       Date:  1991-02       Impact factor: 4.130
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.